Acanthosis nigricans
☆ AI Dermatology — Free Service
Muzotsatira za 2022 Stiftung Warentest zochokera ku Germany, kukhutitsidwa kwa ogula ndi ModelDerm kunali kotsika pang'ono kusiyana ndi kuyankhulana kwa telemedicine komwe kulipiridwa.
Muzotsatira za 2022 Stiftung Warentest zochokera ku Germany, kukhutitsidwa kwa ogula ndi ModelDerm kunali kotsika pang'ono kusiyana ndi kuyankhulana kwa telemedicine komwe kulipiridwa.
Ndizofala ndi anthu onenepa kwambiri.
relevance score : -100.0%
ReferencesAcanthosis nigricans ndi chiwonetsero cha khungu cha vuto lomwe lili pansi. Nthawi zambiri amawonekera pa khungu monga m'khondo, m'khwapa, ndi groin, zowoneka ngati brown‑to‑black, wopanda malire, wopanda kulimba, ndi hyperpigmentation (hyperpigmentation) ya khungu. Matendawa nthawi zambiri amakhudzana ndi matenda a shuga (diabetes mellitus) komanso kukana kwa insulin (insulin resistance), koma nthawi zina, amatha kukhala chiwonetsero cha khansa mkati mwa thupi (internal malignancy). Zitha kuwonekeranso chifukwa cha vuto la mahomoni kapena kugwiritsa ntchito mankhwala ena monga ma steroids (systemic glucocorticoids) ndi mapiritsi oletsa kubereka (oral contraceptives).
Acanthosis nigricans is a cutaneous manifestation of an underlying condition. It usually develops in skin folds, such as the back of the neck, axilla, and groin, where it presents as velvety hyper-pigmented patches with poorly defined borders. Acanthosis nigricans is most commonly associated with diabetes and insulin resistance, but rarely it can be a sign of internal malignancy. It can also occur with hormone disorders or with the use of certain medications like systemic glucocorticoids and oral contraceptives.
Acanthosis nigricans is a cutaneous manifestation of an underlying condition. It usually develops in skin folds, such as the back of the neck, axilla, and groin, where it presents as velvety hyper-pigmented patches with poorly defined borders. Acanthosis nigricans is most commonly associated with diabetes and insulin resistance, but rarely it can be a sign of internal malignancy. It can also occur with hormone disorders or with the use of certain medications like systemic glucocorticoids and oral contraceptives.
Acanthosis nigricans (AN) ndi vuto la khungu lomwe limakhalapo ndi zovuta zosiyanasiyana zaumoyo monga insulin resistance (kuchita kwa insulin), matenda a shuga (diabetes mellitus), kuthana kwambiri (obesity), matenda a khansa (cancers), ndi zovuta za mahomoni monga hypothyroidism, acromegaly, polycystic ovary disease, ndi Cushing's disease. Kuchiza AN kumayang'ana kwambiri kuthana ndi mavuto omwe amayambitsa matenda. Poyamba, madokotala amafufuza zizindikiro za insulin resistance syndrome, zomwe zimaphatikizapo kuthana kwambiri, cholesterol yambiri, kuthamanga kwa magazi, ndi matenda a shuga a mtundu wachiwiri. Madokotala nthawi zambiri amalemba topical retinoids ngati chithandizo choyamba, chomwe chingathandize pakukhuthala kwa khungu. Komabe, sichikuthandiza mdima wa khungu. Njira zina zothandizira (salicylic acid, podophyllin, urea, calcipotriol) zimafunikanso kugwiritsa ntchito pafupipafupi.
Acanthosis nigricans (AN) is a common dermatologic manifestation of systemic disease that is associated with insulin resistance, diabetes mellitus, obesity, internal malignancy, endocrine disorders, and drug reactions. Treatment of AN primarily focuses on resolution of the underlying disease processes causing the velvety, hyperpigmented, hyperkeratotic plaques found on the skin. Initial considerations for the AN workup include evaluating patients for insulin resistance syndrome characterized by obesity, dyslipidemia, hypertension, and diabetes mellitus type II. For cosmetic treatment, topical retinoids are considered the first-line therapy for insulin-resistant AN by modifying keratinization rate. However, topical tretinoin requires application for long durations and improves hyperkeratosis, but not hyperpigmentation. Topical salicylic acid, podophyllin, urea, and calcipotriol also require frequent application, while TCA peels may provide a faster and less time-intense burden.
Acanthosis nigricans (AN) is a common dermatologic manifestation of systemic disease that is associated with insulin resistance, diabetes mellitus, obesity, internal malignancy, endocrine disorders, and drug reactions. Treatment of AN primarily focuses on resolution of the underlying disease processes causing the velvety, hyperpigmented, hyperkeratotic plaques found on the skin. Initial considerations for the AN workup include evaluating patients for insulin resistance syndrome characterized by obesity, dyslipidemia, hypertension, and diabetes mellitus type II. For cosmetic treatment, topical retinoids are considered the first-line therapy for insulin-resistant AN by modifying keratinization rate. However, topical tretinoin requires application for long durations and improves hyperkeratosis, but not hyperpigmentation. Topical salicylic acid, podophyllin, urea, and calcipotriol also require frequent application, while TCA peels may provide a faster and less time-intense burden.
○ Zifukwa
Amapezeka mwa anthu ochepera zaka 40, amatha kutengera chibadwa ndipo amalumikizidwa ndi kunenepa kwambiri (obesity) kapena matenda am'mimba, monga hypothyroidism, acromegaly, polycystic ovary matenda, matenda a diabetes osamva insulin (insulin‑resistant diabetes) kapena matenda a Cushing.
○ Chithandizo ― OTC Mankhwala
#40% urea cream